Chinese biotech startup GenFleet Therapeutics has secured nearly 400 million yuan ($58 million) in a Series B round of financing jointly led by Beijing-based alternative asset management firm CDH Investments, and a healthcare industry fund of government-led Shenzhen Capital Group.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
